{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:25:30Z","timestamp":1791833130293,"version":"4.3.4"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"21","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA265997"],"award-info":[{"award-number":["R01CA265997"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01BX005595"],"award-info":[{"award-number":["I01BX005595"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA268935"],"award-info":[{"award-number":["T32CA268935"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["IRG-21-144-270"],"award-info":[{"award-number":["IRG-21-144-270"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>MRTX1133 is currently being evaluated in patients with pancreatic ductal adenocarcinoma (PDAC) tumors harboring a KRASG12D mutation. Combination strategies have the potential to enhance the efficacy of MRTX1133 to further promote cell death and tumor regression. In this study, we demonstrated that MRTX1133 increased the levels of the proapoptotic protein BIM in PDAC cells and conferred sensitivity to the FDA-approved BCL2 inhibitor venetoclax. Combined treatment with MRTX1133 and venetoclax resulted in cell death and growth suppression in 3D cultures. BIM was required for apoptosis induced by the combination treatment. Consistently, BIM was induced in tumors treated with MRTX1133, and venetoclax enhanced the efficacy of MRTX1133 in vivo. Venetoclax could also resensitize MRTX1133-resistant PDAC cells to MRTX1133 in 3D cultures, and tumors established from resistant cells responded to the combination of MRTX1133 and venetoclax. These results provide a rationale for the clinical testing of MRTX1133 and venetoclax in patients with PDAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The combination of MRTX1133 and the FDA-approved drug venetoclax promotes cancer cell death and tumor regression in pancreatic ductal adenocarcinoma, providing rationale for testing venetoclax with KRASG12D inhibitors in patients with pancreatic cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-23-3574","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T16:22:53Z","timestamp":1723566173000},"page":"3629-3639","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Targeting BCL2 with Venetoclax Enhances the Efficacy of the\n                    <i>KRAS<\/i>\n                    G12D Inhibitor MRTX1133 in Pancreatic Cancer"],"prefix":"10.1158","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7645-2466","authenticated-orcid":false,"given":"Jeffrey H.","family":"Becker","sequence":"first","affiliation":[{"name":"1Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."},{"name":"2Jesse Brown VA Medical Center, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-6270","authenticated-orcid":false,"given":"Anastasia E.","family":"Metropulos","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."},{"name":"2Jesse Brown VA Medical Center, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3658-421X","authenticated-orcid":false,"given":"Christina","family":"Spaulding","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."},{"name":"2Jesse Brown VA Medical Center, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5638-2795","authenticated-orcid":false,"given":"Alejandra M.","family":"Marinelarena","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3562-9875","authenticated-orcid":false,"given":"Mario A.","family":"Shields","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."},{"name":"3The Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4355-6597","authenticated-orcid":false,"given":"Daniel R.","family":"Principe","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7547-0945","authenticated-orcid":false,"given":"Thao D.","family":"Pham","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."},{"name":"3The Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9552-0775","authenticated-orcid":false,"given":"Hidayatullah G.","family":"Munshi","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."},{"name":"2Jesse Brown VA Medical Center, Chicago, Illinois."},{"name":"3The Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"2026042014300192600_bib1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41571-019-0281-6","article-title":"From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer","volume":"17","author":"Nevala-Plagemann","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2026042014300192600_bib2","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026042014300192600_bib3","doi-asserted-by":"crossref","first-page":"108111","DOI":"10.1016\/j.pharmthera.2022.108111","article-title":"The immune modifying effects of chemotherapy and advances in chemo-immunotherapy","volume":"236","author":"Principe","year":"2022","journal-title":"Pharmacol Ther"},{"key":"2026042014300192600_bib4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1172\/JCI59227","article-title":"Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice","volume":"122","author":"Collins","year":"2012","journal-title":"J Clin Invest"},{"key":"2026042014300192600_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"2026042014300192600_bib6","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-21-1331","article-title":"Expanding the reach of precision oncology by drugging all KRAS mutants","volume":"12","author":"Hofmann","year":"2022","journal-title":"Cancer Discov"},{"key":"2026042014300192600_bib7","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res"},{"key":"2026042014300192600_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N Engl J Med"},{"key":"2026042014300192600_bib9","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRASG12C mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026042014300192600_bib10","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","article-title":"A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer","volume":"30","author":"Wei","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026042014300192600_bib11","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat Med"},{"key":"2026042014300192600_bib12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41568-024-00679-6","article-title":"Combinatorial strategies to target RAS-driven cancers","volume":"24","author":"Perurena","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"2026042014300192600_bib13","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat Med"},{"key":"2026042014300192600_bib14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov"},{"key":"2026042014300192600_bib15","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"key":"2026042014300192600_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026042014300192600_bib17","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1007\/s12094-022-03070-9","article-title":"Bcl-2 pathway inhibition in solid tumors: a review of clinical trials","volume":"25","author":"Ploumaki","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"2026042014300192600_bib18","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1158\/2159-8290.CD-21-1334","article-title":"Adapted to survive: targeting cancer cells with BH3 mimetics","volume":"12","author":"Montero","year":"2022","journal-title":"Cancer Discov"},{"key":"2026042014300192600_bib19","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","article-title":"Phosphorylation of Bim-EL by Erk1\/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function","volume":"22","author":"Luciano","year":"2003","journal-title":"Oncogene"},{"key":"2026042014300192600_bib20","doi-asserted-by":"crossref","first-page":"18811","DOI":"10.1074\/jbc.M301010200","article-title":"Activation of the ERK1\/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim","volume":"278","author":"Ley","year":"2003","journal-title":"J Biol Chem"},{"key":"2026042014300192600_bib21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1158\/1535-7163.MCT-18-0413","article-title":"Combined MEK and BCL-2\/XL inhibition is effective in high-grade serous ovarian cancer patient-derived xenograft models and BIM levels are predictive of responsiveness","volume":"18","author":"Iavarone","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"2026042014300192600_bib22","doi-asserted-by":"crossref","first-page":"110441","DOI":"10.1016\/j.celrep.2022.110441","article-title":"G\u03b113 loss in Kras\/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin","volume":"38","author":"Shields","year":"2022","journal-title":"Cell Rep"},{"key":"2026042014300192600_bib23","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/ncb3340","article-title":"Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis","volume":"18","author":"Nielsen","year":"2016","journal-title":"Nat Cell Biol"},{"key":"2026042014300192600_bib24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0091-679X(02)69013-2","article-title":"Analysis of matrix degradation","volume":"69","author":"Munshi","year":"2002","journal-title":"Methods Cell Biol"},{"key":"2026042014300192600_bib25","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1038\/s41467-022-32806-y","article-title":"Spatiotemporal dynamics of self-organized branching in pancreas-derived organoids","volume":"13","author":"Randriamanantsoa","year":"2022","journal-title":"Nat Commun"},{"key":"2026042014300192600_bib26","first-page":"3239","article-title":"Quantification of regenerative potential in primary human mammary epithelial cells","volume":"142","author":"Linnemann","year":"2015","journal-title":"Development"},{"key":"2026042014300192600_bib27","doi-asserted-by":"crossref","first-page":"e152731","DOI":"10.1172\/jci.insight.152731","article-title":"Inhibition of MNKs promotes macrophage immunosuppressive phenotype to limit CD8+ T cell antitumor immunity","volume":"7","author":"Pham","year":"2022","journal-title":"JCI Insight"},{"key":"2026042014300192600_bib28","doi-asserted-by":"crossref","first-page":"e2200143119","DOI":"10.1073\/pnas.2200143119","article-title":"Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer","volume":"119","author":"Principe","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026042014300192600_bib29","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1158\/1535-7163.MCT-13-0925","article-title":"BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen","volume":"13","author":"Sahai","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"2026042014300192600_bib30","doi-asserted-by":"crossref","first-page":"22605","DOI":"10.18632\/oncotarget.25194","article-title":"Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-R\u03b1 mutations","volume":"9","author":"Senkevitch","year":"2018","journal-title":"Oncotarget"},{"key":"2026042014300192600_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1158\/1535-7163.MCT-18-0768","article-title":"Induction of MNK kinase-dependent eIF4E phosphorylation by inhibitors targeting BET proteins limits efficacy of BET inhibitors","volume":"18","author":"Pham","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"2026042014300192600_bib32","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nrc949","article-title":"Pancreatic cancer biology and genetics","volume":"2","author":"Bardeesy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2026042014300192600_bib33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1042\/BJ20111240","article-title":"Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression","volume":"441","author":"Shields","year":"2012","journal-title":"Biochem J"},{"key":"2026042014300192600_bib34","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1158\/0008-5472.CAN-23-2504","article-title":"The extracellular niche and tumor microenvironment enhance KRAS inhibitor efficacy in pancreatic cancer","volume":"84","author":"Kumarasamy","year":"2024","journal-title":"Cancer Res"},{"key":"2026042014300192600_bib35","doi-asserted-by":"crossref","first-page":"a031435","DOI":"10.1101\/cshperspect.a031435","article-title":"KRAS: the critical driver and therapeutic target for pancreatic cancer","volume":"8","author":"Waters","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026042014300192600_bib36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"2026042014300192600_bib37","doi-asserted-by":"crossref","first-page":"41902","DOI":"10.18632\/oncotarget.5881","article-title":"Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL","volume":"6","author":"Hari","year":"2015","journal-title":"Oncotarget"},{"key":"2026042014300192600_bib38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40265-024-02030-7","article-title":"Targeting KRASG12C in non-small-cell lung cancer: current standards and developments","volume":"84","author":"Torres-Jimenez","year":"2024","journal-title":"Drugs"},{"key":"2026042014300192600_bib39","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","article-title":"Efficacy and safety of adagrasib plus cetuximab in patients with KRASG12C-mutated metastatic colorectal cancer","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov"},{"key":"2026042014300192600_bib40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N Engl J Med"},{"key":"2026042014300192600_bib41","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","article-title":"Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor","volume":"172","author":"Janes","year":"2018","journal-title":"Cell"},{"key":"2026042014300192600_bib42","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41467-017-00942-5","article-title":"Survival of pancreatic cancer cells lacking KRAS function","volume":"8","author":"Muzumdar","year":"2017","journal-title":"Nat Commun"},{"key":"2026042014300192600_bib43","doi-asserted-by":"crossref","first-page":"e13026","DOI":"10.1371\/journal.pone.0013026","article-title":"Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim","volume":"5","author":"Meng","year":"2010","journal-title":"PLoS One"},{"key":"2026042014300192600_bib44","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1371\/journal.pmed.0040316","article-title":"Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics","volume":"4","author":"Cragg","year":"2007","journal-title":"PLoS Med"},{"key":"2026042014300192600_bib45","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1172\/JCI35437","article-title":"Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic","volume":"118","author":"Cragg","year":"2008","journal-title":"J Clin Invest"},{"key":"2026042014300192600_bib46","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1158\/1078-0432.CCR-08-3294","article-title":"Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma","volume":"15","author":"Ou","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026042014300192600_bib47","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1158\/1535-7163.MCT-12-0949","article-title":"Bcl-2\/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models","volume":"12","author":"Tan","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"2026042014300192600_bib48","doi-asserted-by":"crossref","first-page":"1130034","DOI":"10.3389\/fonc.2023.1130034","article-title":"MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma","volume":"13","author":"Eleveld","year":"2023","journal-title":"Front Oncol"},{"key":"2026042014300192600_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ccr.2012.11.007","article-title":"Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models","volume":"23","author":"Corcoran","year":"2013","journal-title":"Cancer Cell"},{"key":"2026042014300192600_bib50","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-23-3574\/3484988\/can-23-3574.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/84\/21\/3629\/3511071\/can-23-3574.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/84\/21\/3629\/3511071\/can-23-3574.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T18:30:21Z","timestamp":1776709821000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/84\/21\/3629\/749278\/Targeting-BCL2-with-Venetoclax-Enhances-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":50,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,8,13]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-23-3574","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.27603366","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27603378","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27603357","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27603369","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27603384","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27603375","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27603387","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27603360","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27603393","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.7523007","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]}}}